Spain CAR-T Cell Therapy Market to Grow with a CAGR of 67.28% through 2028
Robust research and development,
supportive regulatory measures and enhanced access are expected to
drive the Spain CAR-T Cell Therapy Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Spain CAR-T
Cell Therapy Market –Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2028”, the Spain CAR-T Cell Therapy Market stood at
USD 52.36 million in 2022 and is anticipated to grow with a CAGR of 67.28% in
the forecast period, 2024-2028. This can be attributed to Access and
Reimbursement. Access to CAR-T therapy has expanded in Spain, thanks to
progressive healthcare policies and reimbursement mechanisms. Health
authorities have recognized the potential of CAR-T therapy and have taken steps
to make it accessible to eligible patients. The availability of reimbursement
for these high-cost therapies has been instrumental in promoting patient access
and driving market growth. With the increasing use of CAR-T therapy in clinical
practice, there is a growing emphasis on real-world data and outcomes.
Gathering and analyzing information from patients receiving CAR-T treatment
will provide insights into the therapy's long-term effectiveness, safety, and
potential side effects. This data will be valuable for healthcare
decision-makers, regulatory bodies, and future treatment guidelines.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Spain CAR-T Cell Therapy Market.”
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an
innovative and promising immunotherapy approach used to treat certain types of
cancer. In Spain, the CAR-T cell therapy market was experiencing growth and
development, mirroring global trends in the field. Spain had several leading
hospitals and medical centers that offered CAR-T cell therapy, with a focus on
major cities like Madrid and Barcelona. These facilities played a significant
role in the development of the market. As of 2022, CAR-T cell therapies were
approved for the treatment of certain blood cancers, such as relapsed or
refractory B-cell acute lymphoblastic leukemia (ALL) and relapsed or refractory
B-cell lymphomas.
The Spain CAR-T Cell Therapy Market is segmented into
product type, tumor type, indication,
treatment
type, targeted antigen, end user, regional distribution, and company.
Based on its tumor type, Hematological malignancies
are poised to dominate the CAR-T cell therapy market in Spain for several
compelling reasons. Firstly, Spain has a higher prevalence of hematological
malignancies, such as leukemia, lymphoma, and multiple myeloma, which makes it
a prime target for innovative treatments like CAR-T cell therapy. Secondly, the
country has a well-established healthcare infrastructure with a strong focus on
research and development in the field of oncology. This enables rapid adoption
of advanced therapies and a robust clinical trial ecosystem for CAR-T cell therapies.
Additionally, the Spanish government and healthcare agencies have shown a
commitment to expedite the approval and reimbursement processes for novel
therapies, providing a favorable regulatory environment for CAR-T treatments.
All these factors combined indicate a promising future for hematological
malignancy treatments through CAR-T cell therapy in Spain, leading to its
dominance in the market.
Based on indication, Follicular Lymphoma (FL) is set
to play a dominant role in the Spain CAR-T cell therapy market for several
compelling reasons. FL is one of the most prevalent subtypes of non-Hodgkin
lymphoma in Spain, making it a significant healthcare concern. CAR-T cell
therapy has shown remarkable efficacy in treating refractory and relapsed FL
patients, offering a promising solution to a previously unmet medical need.
Moreover, Spain boasts a robust infrastructure for cancer care, with
specialized treatment centers and a well-established network of oncologists,
further facilitating the adoption and administration of CAR-T therapies. The
regulatory environment in Spain is also conducive, with authorities actively
supporting innovative treatments, which expedites the approval and
reimbursement processes. All these factors align to create a favorable
landscape for the dominance of Follicular Lymphoma in the Spain CAR-T cell
therapy market, potentially transforming the landscape of FL treatment in the
country.
Major companies operating in Spain CAR-T Cell Therapy Market
are:
- Gilead Sciences, Inc
- Novartis International AG
- Bristol Myers Squibb Co
- Abbvie Spain, S.L.U.
- AMGEN S.A.
- Pfizer Inc
- Merck & Co. Inc
- Johnson & Johnson S.A.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The CAR-T cell therapy market in Spain is on the cusp
of a transformative era. As the field of CAR-T therapy continues to evolve,
emerging trends in expanding indications, advanced technologies, personalized
medicine, and innovative combination therapies are set to redefine cancer
treatment. With regulatory support, real-world data, and improved patient
access, Spain's CAR-T cell therapy market is poised to play a pivotal role in
revolutionizing the way cancer is treated, offering new hope to patients facing
previously insurmountable challenges,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Spain CAR-T Cell Therapy Market By Product
Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others),
By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication
(Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL),
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment
Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19,
BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty
Clinics, Ambulatory Surgical Centers, Others), By
Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Spain CAR-T Cell Therapy Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Spain CAR-T Cell Therapy Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com